Stephen G. Marcus, M.D., is a medical oncologist and pharmaceutical executive who has led the development of several profitable pharmaceutical and biotechnology products. Dr. Marcus led the development of Betaseron, the first effective treatment for multiple sclerosis, and was instrumental in the development of Intron A, Temodar, Fludara, and brand-equivalent Paclitaxel.
Dr. Marcus is the inventor of our U.S. Patent 8,734,804, entitled “Treatment of Myelosuppression.”
Neil W. Flanzraich was the Vice Chairman and President of IVAX Corporation until it was sold to Teva Pharmaceutical Industries Limited in 2006. Before that, he served as Senior Vice President and Chief Counsel at Syntex Corporation and a member of its Executive and Operating Committees prior to its sale to Roche in 1994. Mr. Flanzraich was an early investor in Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director. In addition, Mr. Flanzraich is an independent director of Atrium European Real Estate Limited (VSE/Euronext:ATRS), and an expert-in-residence for an entrepreneurship program at Harvard Law School and Harvard Business School.
Juan F. Rodriguez has served as our Chief Financial Officer since November 2014, bringing more than 20 years of financial and business leadership experience to Cantex, the majority of which has been in the life sciences field. Before joining Cantex, Mr. Rodriguez served as Chief Financial Officer at OPKO Health, Inc. (NYSE: OPK). Prior to that he served as a consultant to Cognitec Systems GmbH, a German software developer, and currently serves as the Chairman of Cognitec’s Advisory Board. Prior to that, Mr. Rodriguez was with Kos Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company (which was later acquired by Abbott Laboratories), last serving as Senior Vice President, Controller and Corporate Administration.